Journal
GENOME MEDICINE
Volume 11, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13073-019-0631-0
Keywords
-
Categories
Funding
- Department of Defense (USA) Congressionally Directed Medical Research grant [W81XWH-15-1-0210]
Ask authors/readers for more resources
As trials of immune checkpoint inhibitor (ICI) therapies demonstrate responses in only a minority of pleural mesotheliomas (PlMs) and largely exclude patients with the related peritoneal mesothelioma (PeM), clinicians need predictive biomarkers of response and inclusion of PeM patients in future trials. A new study finds that loss of the deubiquitinase BAP1 in PeM correlates with an inflammatory tumor microenvironment, suggesting that BAP1 status might identify PeM, and possibly PlM, patients who would benefit from ICI therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available